title: Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model.
abstract: ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.
authors.affiliation: Origenix Techonologies, Inc., St. Laurent, Quebec, Canada.
authors.forename: Radhakrishnan P
authors.initials: RP
authors.lastname: Iyer
authors.forename: Arlene
authors.initials: A
authors.lastname: Roland
authors.forename: Yi
authors.initials: Y
authors.lastname: Jin
authors.forename: Samir
authors.initials: S
authors.lastname: Mounir
authors.forename: Brent
authors.initials: B
authors.lastname: Korba
authors.forename: Justin G
authors.initials: JG
authors.lastname: Julander
authors.forename: John D
authors.initials: JD
authors.lastname: Morrey
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015139:Blotting, Southern; D004279:DNA, Viral / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics*; D007274:Injections, Intraperitoneal; D008099:Liver / Q000378:metabolism / Q000821:virology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009841:Oligonucleotides / Q000008:administration & dosage / Q000494:pharmacology; D012367:RNA, Viral / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; C487657:ORI 9020; D009841:Oligonucleotides; D012367:RNA, Viral